Patents Issued in May 6, 2021
  • COMPOSITION, USES, AND METHODS OF TREATING SPINAL DISC DEGENERATION THROUGH SONIC HEDGEHOG SIGNALING PATHWAY
    Publication number: 20210128540
    Abstract: Presented herein are methods for treating spinal disc degeneration (SDD) by administering to a subject in need thereof, an amount of a SHE signaling pathway activator effective for treating the subject.
    Type: Application
    Filed: June 23, 2018
    Publication date: May 6, 2021
    Inventor: Chitra DAHIA
  • ANDROGEN RECEPTOR INHIBITORS FOR THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN SUBJECTS WITH SEVERE HEPATIC IMPAIRMENT
    Publication number: 20210128541
    Abstract: Described herein are methods of treating non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment with androgen receptor inhibitors, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Inventors: Caly Chien, Peter Hellemans, Alex Yu
  • VETERINARY PHARMACEUTICAL COMPOSITIONS FOR DIRECT SYSTEMIC INTRODUCTION
    Publication number: 20210128542
    Abstract: Veterinary pharmaceutical compositions for direct systemic introduction, also known as DSI pharmaceutical compositions. One veterinary pharmaceutical composition for direct systemic introduction includes about 10-17 dry mass % bovine gelatin; about 10-17 dry mass % mannitol; about 0-1 dry mass % of a surfactant; and about 65-80 dry mass % of the active pharmaceutical ingredient which is a proton pump inhibitor. A method of manufacturing a veterinary pharmaceutical composition for direct systemic introduction includes combining one or more pharmacologically inactive compounds to form a first solution; using one or more surfactants to form a second solution; adding an active pharmaceutical ingredient to the second solution to form a first mixture; adding the first solution to the first mixture to form a pre-formulation; freezing the pre-formulation; and lyophilizing the pre-formulation.
    Type: Application
    Filed: January 13, 2021
    Publication date: May 6, 2021
    Applicant: NewMarket Pharmaceuticals LLC
    Inventors: Mark RIDALL, David ROCK
  • METHODS OF TREATMENT
    Publication number: 20210128543
    Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.
    Type: Application
    Filed: October 28, 2020
    Publication date: May 6, 2021
    Inventors: Sundar SRINIVASAN, Christina CHOW
  • OPHTHALMIC COMPOSITIONS COMPRISING BILASTINE, A BETA-CYCLODEXTRIN AND AT LEAST ONE GELLING AGENT
    Publication number: 20210128544
    Abstract: The invention relates to an aqueous ophthalmic pharmaceutical composition comprising: a) at least 0.4% w/v of bilastine, of formula or a pharmaceutically acceptable salt or solvate thereof, wherein the bilastine salt or solvate thereof is completely dissolved in the pharmaceutical composition; b) at least one ?-cyclodextrin; and c) at least one pharmaceutically acceptable water-soluble gelling agent; and wherein the pH is comprised between 4 and 9. and its use in the treatment and/or prevention of conditions mediated by H1 histamine receptor, such as allergic disorders or diseases. The invention relates to the treatment and/or prevention of allergic conjunctivitis.
    Type: Application
    Filed: January 9, 2019
    Publication date: May 6, 2021
    Inventors: Gonzalo HERNÁNDEZ HERRERO, Ana GONZALO GOROSTIZA, Pablo MORAN POLADURA, Arturo ZAZPE ARCE, Nieves FERNANDEZ HERNANDO, Tania GONZALEZ GARCIA, Paloma TATO CERDEIRAS, Francisco Javier OTERO ESPINAR, Anxo FERNANDEZ FERREIRO, Victoria DIAZ TOME
  • COMBINATION THERAPY WITH 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE
    Publication number: 20210128545
    Abstract: Provided herein are methods of treating, preventing, managing, and/or ameliorating hypotension related to administration of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cancer patient, wherein the methods comprise administering a combination comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and a glucocorticoid receptor agonist, an interleukin-1 receptor antagonist, or an interleukin-1? blocker.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Inventors: Tonia Buchholz, Jinhong Fan, Daniel W. Pierce, Michael Pourdehnad, Sheena Yao
  • Atropine Pharmaceutical Compositions
    Publication number: 20210128546
    Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
    Type: Application
    Filed: January 11, 2021
    Publication date: May 6, 2021
    Applicant: Nevakar Inc.
    Inventors: Kumaresh Soppimath, Tushar Hingorani
  • AGGRESSIVE LIPID LOWERING THERAPY IN CORONARY ARTERY DISEASE
    Publication number: 20210128547
    Abstract: Methods of further reducing cardiovascular risk in subjects with coronary artery disease on moderate intensity statins. For example, methods may prevent an adverse cardiovascular event in a subject in need thereof, on a dosage of 1 mg/day pitavastatin or a pharmaceutically acceptable salt thereof, when the subject has an LDL-C concentration less than 120 mg/dL, by increasing the dosage to 4 mg/day for a therapeutically effective period of time.
    Type: Application
    Filed: May 11, 2018
    Publication date: May 6, 2021
    Inventor: Toshio TAKANO
  • EXTERNAL PREPARATION COMPRISING PYRIDONECARBOXYLIC ACID DERIVATIVE
    Publication number: 20210128548
    Abstract: The present invention is intended mainly to provide an external preparation that exerts a therapeutic and/or preventive effect against dermatological infections such as acne involving suppurative inflammation, and superficial infections of the skin upon being administered to a human patient once daily. For example, the present invention is an external preparation that comprises 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid and/or a pharmaceutically acceptable salt thereof as an active ingredient, and that exerts a therapeutic and/or preventive effect against a dermatological infection upon being administered to a human patient once daily.
    Type: Application
    Filed: January 8, 2021
    Publication date: May 6, 2021
    Applicant: MARUHO CO., LTD.
    Inventors: Akira FUJIKAWA, Hiroshi YAMADA
  • OXYCODONE AND METHYLNALTREXONE MULTIPARTICULATES AND SUSPENSIONS CONTAINING THEM
    Publication number: 20210128549
    Abstract: The invention relates to a composition that can be administered orally, comprising (a) opioid multi-particulates comprising an opioid active agent, and an abuse resistant release controlling agent; and (b) opioid antagonist multi-particulates comprising an opioid antagonist, and a release controlling agent and/or a release delaying agent. It also relates to a liquid suspension that can be administered orally, comprising (a) opioid multi-particulates comprising an opioid active agent, and an abuse resistant release controlling agent; and/or (b) opioid antagonist multi-particulates comprising an opioid antagonist, and a release controlling agent and/or a release delaying agent; and wherein the multi-particulates are suspended in a liquid comprising a viscosity modifier and a flavoring agent. The invention also relates to kits containing these multi-particulates, and methods of making and using them.
    Type: Application
    Filed: February 28, 2019
    Publication date: May 6, 2021
    Applicant: CELISTA PHARMACEUTICALS LLC
    Inventors: Yogesh DANDIKER, Maulik Kiritkumar PANCHAL, Xiao YU
  • AMELIORATIVE AGENT FOR CYTOKINE RELEASE SYNDROME AND SO ON
    Publication number: 20210128550
    Abstract: [Problem to be Solved] The present invention provides a medicament for cytokine release syndrome, autoimmune-related adverse events, macrophage activation syndrome, hemophagocytic lymphohistiocytosis or Langerhans cell histiocytosis. [Means to Solve the Problem] The present invention provides a medicament for at least one selected from the group consisting of cytokine release syndrome, autoimmune-related adverse events, macrophage activation syndrome, hemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis, wherein the medicament comprises a compound represented by the following formula I: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 29, 2019
    Publication date: May 6, 2021
    Applicant: TORII PHARMACEUTICAL CO., LTD.
    Inventors: Yoshihiro WATANABE, Yoshio TAHARA, Keisuke SUZUKI, Takayuki MIMURA, Saori OHMAE
  • PROCASPASE 3 ACTIVATION BY COMBINATION THERAPY
    Publication number: 20210128551
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Application
    Filed: January 8, 2021
    Publication date: May 6, 2021
    Applicants: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.
    Inventors: Paul J. HERGENROTHER, Rachel C. BOTHAM, Timothy M. FAN, Mark J. GILBERT, Michael K. HANDLEY, Howard S. ROTH, Theodore M. TARASOW
  • IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
    Publication number: 20210128552
    Abstract: Imidazo[1,2-?]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia, dyssomnia, parasomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.
    Type: Application
    Filed: September 9, 2020
    Publication date: May 6, 2021
    Inventors: Yifeng XIONG, Konrad FEICHTINGER, Albert S. REN, Brett ULLMAN
  • COMBINATION COMPOSITIONS FOR IMMUNOTHERAPY
    Publication number: 20210128553
    Abstract: The present invention relates to therapeutic combinations comprising WNT inhibitors and methods for treating cancers using combination therapy.
    Type: Application
    Filed: October 12, 2020
    Publication date: May 6, 2021
    Inventors: Xiaoli Qin, Songzhu An, Tao Huang
  • ANTI-FLAVIVIRIDAE ACTIVITY OF ANTI-RETROVIRAL NON-NUCLEOSIDE (NNRTIS) AND NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)
    Publication number: 20210128554
    Abstract: Compositions of non-nucleoside reverse transcriptase inhibitor (NNRTI) and/or a nucleoside reverse transcriptase inhibitor (NRTI) or combinations thereof, in the prevention and treatment of Flaviviridae infections, e.g. Zika virus.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 6, 2021
    Inventor: Kamel Khalili
  • CDK4/6 INHIBITORS AND USE THEREOF
    Publication number: 20210128555
    Abstract: The present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, a solvate, a stereoisomer, or tautomer thereof, a pharmaceutical composition comprising a compound of formula (A) or formula (B), and any subgenera thereof, and use of said compounds and compositions thereof, wherein R1, R2, R3a, R3b, R5, R6, X1, X2, Y and n are described herein.
    Type: Application
    Filed: August 15, 2018
    Publication date: May 6, 2021
    Inventors: Yuntao SONG, Xiaoqi CHEN
  • AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20210128556
    Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: June 16, 2020
    Publication date: May 6, 2021
    Inventors: Daniel L. Flynn, Yu Mi Ahn, Timothy Caldwell, Lakshminarayana Vogeti
  • METHODS AND COMPOSITIONS FOR PREDICTING AND PREVENTING RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA
    Publication number: 20210128557
    Abstract: Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof or any combination thereof.
    Type: Application
    Filed: October 30, 2020
    Publication date: May 6, 2021
    Inventors: Alexander K. Shalek, Peter Winter, David Weinstock, Mark Murakami, Scott Manalis, Andrew Navia, Jennyfer Galvez-Reyes
  • Treatment Of Adipocytes
    Publication number: 20210128558
    Abstract: The present disclosure provides compositions comprising a lyn kinase activator and TRPM8 agonist, and to methods of: reducing blood glucose levels, weight gain, or fat depot levels; treating metabolic syndrome, Syndrome X, obesity, prediabetes, type II diabetes, type I diabetes; treating hypercholesterolemia, hypertension, coronary heart disease, diabetic neuropathy, lipodystrophy, diabetic retinopathy, erectile dysfunction, kidney disease, dyslipidemia, dyslipoproteinemia, a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, or pancreatitis; inducing the beiging of adipocytes; and preventing pancreatic beta cell degeneration.
    Type: Application
    Filed: August 19, 2020
    Publication date: May 6, 2021
    Inventors: Andrew G. Reaume, Weina Cong, Frank Greenway, Ann Coulter
  • Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof
    Publication number: 20210128559
    Abstract: The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and/or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders or neurological diseases.
    Type: Application
    Filed: December 26, 2017
    Publication date: May 6, 2021
    Inventors: Heng XU, Xiaoguang CHEN, Songwen LIN, Ming JI, Jing JIN, Deyu WU, Chunyang WANG, Yuanhao LV
  • PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS
    Publication number: 20210128560
    Abstract: The present invention relates to a compound that is useful as an inhibitor of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising this compound and to methods of using this compound in the treatment of cancer and methods of treating cancer.
    Type: Application
    Filed: March 12, 2018
    Publication date: May 6, 2021
    Inventors: Peter HEWITT, Frank BURKAMP, Andrew WILKINSON, Hugues MIEL, Colin O'DOWD
  • MRGX Receptor Antagonists
    Publication number: 20210128561
    Abstract: The invention relates to a method for preventing or treating a disease or disorder that is associated with the MrgX2 receptor. The invention also relates to MrgX2 antagonists and physiologically acceptable salts thereof. The invention also relates to pharmaceutical compositions and dosage forms comprising an MrgX2 antagonist.
    Type: Application
    Filed: October 31, 2019
    Publication date: May 6, 2021
    Inventors: Christa Müller, Mohamad Wessam Alnouri, Yvonne Riedel, Dominik Thimm, Daniel Marx, Vigneshwaran Namasivayam, Susanne Gattner, Piet Herdewyn, Steven De Jonghe, Piotr Leonczak, Sven Verdonck
  • INTRAVENOUS INFUSION DOSAGE FORM
    Publication number: 20210128562
    Abstract: The present invention refers to an intravenous infusion dosage form comprising a composition containing pemetrexed or its pharmaceutically acceptable salt, an osmagent and an aquous vehicle. The composition is present in a flexible infusion container containing an inert gas in the headspace. Additionally, a second container may be present surrounding the flexible infusion container.
    Type: Application
    Filed: November 19, 2020
    Publication date: May 6, 2021
    Applicant: Sun Pharmaceutical Industries Limited
    Inventors: Samarth Kumar, Prashant Kane, Subhas Balaram Bhowmick, Kirti Ganorkar, Nisarg Bipinchandra Mistry, Ramaji Karshanbhai Varu
  • N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20210128563
    Abstract: The invention relates to N-(substituted-phenyl)-sulfonamide compounds, which are extremely useful as inhibitors of protein kinases (e.g. PERK kinase) and accordingly can be used for the treatment of cell proliferative disorders, such as cancer, or diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.
    Type: Application
    Filed: January 4, 2021
    Publication date: May 6, 2021
    Applicant: Nerviano Medical Sciences S.R.L.
    Inventors: Simona Bindi, Davide Carenzi, Ilaria Motto, Maurizio Pulici
  • COMPOSITIONS AND METHODS OF USE OF CIS-4-[2-{[(3S,4R)-3-FLUOROOXAN-4-YL]AMINO}-8-(2,4,6-TRICHLOROANILINO)-9H-PURIN-9-YL]-1-METHYLCYCLOHEXANE-1-CARBOXAMIDE
    Publication number: 20210128564
    Abstract: Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
    Type: Application
    Filed: December 22, 2020
    Publication date: May 6, 2021
    Inventors: Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang
  • SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20210128565
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Application
    Filed: January 12, 2021
    Publication date: May 6, 2021
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
  • NOVEL FUNCTIONALIZED PURINE-2,6-DIONES AND THEIR USE IN MEDICINE
    Publication number: 20210128566
    Abstract: There is provided compounds of formula (I), or pharmaceutically-acceptable salts thereof, wherein R1 to R4 and X1 to X5 have meanings provided in the description, which compounds are useful in the treatment of cancers.
    Type: Application
    Filed: July 27, 2018
    Publication date: May 6, 2021
    Inventors: Brent PAGE, Nicholas VALERIE, Thomas HELLEDAY, Olov WALLNER, Martin SCOBIE, Sabin LLONA-MINGUEZ
  • Compositions and Methods for Cognitive, Immune and Digestive Support in Patients with Autism Spectrum Disorder
    Publication number: 20210128567
    Abstract: The present invention provides compositions and methods for improving the quality of life for a subject, particularly a child, diagnosed with autism spectrum disorder (ASD). In preferred embodiments, a supplement composition comprising natural or naturally-derived ingredients is delivered to a subject in the form of a chocolate bar or other candy alongside administration of an antiviral medication. Advantageously, the composition and methods can improve the immune health of the subject, along with other signs and symptoms associated with ASD, infections and other immunocompromising conditions.
    Type: Application
    Filed: August 29, 2018
    Publication date: May 6, 2021
    Inventors: Andrew R. LEFKOWITZ, Sean FARMER, Ken ALIBEK, Albina TSKHAY, Alibek MOLDAKOZHAYEV
  • SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME
    Publication number: 20210128568
    Abstract: The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.
    Type: Application
    Filed: September 8, 2020
    Publication date: May 6, 2021
    Inventors: Lingkai Weng, Lei Qiao, Jiacheng Zhou, Pingli Liu, Yongchun Pan
  • ORODISPERSIBLE FORMULATION OF VARDENAFIL
    Publication number: 20210128569
    Abstract: The present invention includes an orodispersible polyalcohol-free formulation containing vardenafil or a pharmaceutically acceptable salt thereof as active ingredient, as well as filler, a buffering agent, a lubricant, a sweetener, a flavoring agent and, optionally, further pharmaceutically acceptable excipients.
    Type: Application
    Filed: October 21, 2020
    Publication date: May 6, 2021
    Applicant: Alpex Pharma S.A.
    Inventors: Federico STROPPOLO, Gabriele GRANATA
  • METHODS FOR TREATING PULMONARY FIBROSIS
    Publication number: 20210128570
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating pulmonary fibrosis. The method comprises a step of administering to a pulmonary fibrosis patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.
    Type: Application
    Filed: January 7, 2021
    Publication date: May 6, 2021
    Inventor: Laxminarayan BHAT
  • 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES
    Publication number: 20210128571
    Abstract: The invention provides novel 6-aryl or 6-heteroaryl 4-morpholin-4-yl-pyhdine-2-one compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, diabetes, inflammatory diseases, neurodegenerative disorders, cardiovascular disorders and viral infections; wherein R1, R2, R3 and R4 are as defined in the specification.
    Type: Application
    Filed: February 17, 2017
    Publication date: May 6, 2021
    Inventors: Jessica MARTINESSON, Martin ANDERSSON, Johan LINDSTRÖM, Rickard FORSBLOM, Fredrik RAHM, Tobias GINMAN, Jenny VIKLUND
  • COMBINATION OF ATR KINASE INHIBITORS WITH PARP INHIBITORS
    Publication number: 20210128572
    Abstract: The present invention covers combinations of at least two components, component A and component B, comprising component A being an ATR kinase inhibitor, particularly Compound A, and component B being a PARP inhibitor, such as olaparib. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment of a hyper-proliferative disease.
    Type: Application
    Filed: February 22, 2018
    Publication date: May 6, 2021
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Antje Margret WENGNER, Gerhard SIEMEISTER
  • DOSING REGIMENS FOR USE IN TREATING MYELOFIBROSIS AND MPN-RELATED DISORDERS WITH NAVITOCLAX
    Publication number: 20210128573
    Abstract: The invention described herein relates to methods for treating a human subject with myelofibrosis or an MPN-related disorder, comprising administering navitoclax to the subject optionally in combination with ruxolitinib.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Inventors: John Hayslip, Leanne M. Holes, Sven Mensing, Silpa Nuthalapati
  • NOVEL USES
    Publication number: 20210128574
    Abstract: This invention relates to new use of dual NK-1/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.
    Type: Application
    Filed: November 6, 2018
    Publication date: May 6, 2021
    Applicant: KaNDy Therapeutics Limited
    Inventor: Mike Trower
  • PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
    Publication number: 20210128575
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Application
    Filed: January 11, 2021
    Publication date: May 6, 2021
    Inventor: Herriot Tabuteau
  • PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
    Publication number: 20210128576
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Application
    Filed: January 13, 2021
    Publication date: May 6, 2021
    Inventor: Herriot Tabuteau
  • Selective HDAC6 Inhibitors
    Publication number: 20210128577
    Abstract: The present invention relates to novel benzohydroxamic compounds of formula (1) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (HDAC6) enzyme.
    Type: Application
    Filed: April 12, 2018
    Publication date: May 6, 2021
    Inventors: Barbara VERGANI, Gianluca CAPRINI, Gianluca FOSSATI, Maria LATTANZIO, Mattia MARCHINI, Gianfranco PAVICH, Marcello PEZZUTO, Chiara RIPAMONTI, Giovanni SANDRONE, Christian STEINKÜHLER, Andrea STEVENAZZI
  • CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE
    Publication number: 20210128578
    Abstract: The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
    Type: Application
    Filed: November 16, 2020
    Publication date: May 6, 2021
    Inventors: Bridget McCarthy Cole, James Lamond Ellis
  • FORMULATIONS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER
    Publication number: 20210128579
    Abstract: Provided herein are compositions for reducing symptoms of post-traumatic stress disorder. The compositions include a combination of an N-methyl-D-aspartate (NMDA) receptor antagonist and an anti-depression agent.
    Type: Application
    Filed: January 1, 2021
    Publication date: May 6, 2021
    Applicant: Glytech LLC
    Inventor: Daniel C. Javitt
  • TREATMENT FOR WOLFRAM SYNDROME AND OTHER ENDOPLASMIC RETICULUM STRESS DISORDERS
    Publication number: 20210128580
    Abstract: The present invention generally relates to compositions and methods for treating or preventing an endoplasmic reticulum stress disorder in subjects, including compositions and methods for treating or preventing Wolfram syndrome. The present invention also relates to methods for treating symptoms of neurodegenerative diseases.
    Type: Application
    Filed: March 6, 2018
    Publication date: May 6, 2021
    Applicants: Washington University, The United States of America, As Represented by the Secretary, Department Health and Human Service
    Inventors: Fumihiko Urano, Jana Mahadevan, Amy Clark, Ajit Jadhav, David Maloney, Brandon Harvey, Shyh-ming Yang, Mark Henderson
  • METHODS OF USE FOR TRP CHANNEL ANTAGONIST-BASED COMBINATION CANCER THERAPIES
    Publication number: 20210128581
    Abstract: The present invention relates to methods for treating cancer through combination therapy with a TRP channel antagonist and standard-of-care cancer agents.
    Type: Application
    Filed: March 5, 2018
    Publication date: May 6, 2021
    Inventors: Joan Siefert BRUGGE, Nobuaki TAKAHASHI
  • METHODS OF TREATING OR PREVENTING NONALCOHOLIC STEATOHEPATITIS AND/OR PRIMARY BILIARY CIRRHOSIS
    Publication number: 20210128582
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing NASH and/or PBC comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Application
    Filed: November 30, 2020
    Publication date: May 6, 2021
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Joe Zakrzewski
  • INJECTABLE NEUROSTEROID FORMULATIONS CONTAINING NANOPARTICLES
    Publication number: 20210128583
    Abstract: The disclosure provides an injectable neurosteroid nanoparticle formulation comprising nanoparticles having a D50 of less than 2000 nm the nanoparticles comprising a neurosteroid of Formula I, where the variables R1-R9 and X are defined herein and at least one surface stabilizer,. The surface stabilizer can be a polymeric surface stabilizer such as hydroxyethyl starch, dextran, or povidone. The injectable neurosteroid nanoparticle formulation can be an intravenous formulation. The disclosure also provides a lyophilized powder of the injectable neurosteroid nanoparticle formulation that can be reconstituted in an aqueous solution prior to administration. The disclosure provides injectable neurosteroid nanoparticle formulations and dry powders of such formulations that have been sterilized by ebeam irradiation.
    Type: Application
    Filed: August 13, 2020
    Publication date: May 6, 2021
    Inventors: Mingbao Zhang, Raymond C. Glowaky, David Czekai
  • USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
    Publication number: 20210128584
    Abstract: The invention generally pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptor can be used in methods for treating patients diagnosed with Amyotrophic Lateral Sclerosis (ALS).
    Type: Application
    Filed: October 16, 2020
    Publication date: May 6, 2021
    Inventor: Joseph K. Belanoff
  • SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
    Publication number: 20210128585
    Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
    Type: Application
    Filed: November 25, 2020
    Publication date: May 6, 2021
    Inventors: Philippe PERRIN, Jose Luis VELADA, Dominique DROUIN
  • METHODS OF SIZING 6B,7B:15B,16B-DIMETHYLENE-3-OXO-17A-PREGN-4-ENE-21,17-CARBOLACTONE PARTICLES AND COMPOSITIONS COMPRISING THE SAME
    Publication number: 20210128586
    Abstract: Described herein are methods to size particles of 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as compositions comprising 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone particles having defined particle size distributions. Also described are methods of use of the resulting particles.
    Type: Application
    Filed: November 25, 2020
    Publication date: May 6, 2021
    Inventors: Philippe PERRIN, Jose Luis VELADA, Dominique DROUIN
  • OMEGA-3 FATTY ACID AND VITAMIN D LEVELS TO IDENTIFY AND ATTENUATE COGNITIVE AGING IN INDIVIDUALS
    Publication number: 20210128587
    Abstract: A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin Dora metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject.
    Type: Application
    Filed: December 11, 2017
    Publication date: May 6, 2021
    Inventors: Gene Bowman, Julie Laure Hudry-Labbe, Jeroen Antonius Johannes Schmitt, Corina Boschat
  • PHARMACEUTICAL SPRAY COMPOSITION COMPRISING A VITAMIN D ANALOGUE AND CORTICOSTEROID
    Publication number: 20210128588
    Abstract: The present invention relates to a topical spray composition comprising a biologically active vitamin D derivative or analogue and a corticosteroid, and its use in the treatment of dermal diseases and conditions.
    Type: Application
    Filed: June 17, 2020
    Publication date: May 6, 2021
    Inventors: Marianne LIND, Gritt RASMUSSEN, Mette Rydahl SONNE, Jens HANSEN, Karsten PETERSSON
  • PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE
    Publication number: 20210128589
    Abstract: The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
    Type: Application
    Filed: November 5, 2020
    Publication date: May 6, 2021
    Inventors: Bridget McCarthy Cole, James Lamond Ellis